Comparing CRISPR Therapeutics (NASDAQ:CRSP) and Genenta Science (NASDAQ:GNTA)

CRISPR Therapeutics (NASDAQ:CRSPGet Free Report) and Genenta Science (NASDAQ:GNTAGet Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Earnings & Valuation

This table compares CRISPR Therapeutics and Genenta Science’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CRISPR Therapeutics $371.21 million 13.97 -$153.61 million ($1.96) -32.96
Genenta Science N/A N/A -$8.93 million N/A N/A

Genenta Science has lower revenue, but higher earnings than CRISPR Therapeutics.


This table compares CRISPR Therapeutics and Genenta Science’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CRISPR Therapeutics N/A -8.09% -6.73%
Genenta Science N/A N/A N/A

Risk and Volatility

CRISPR Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for CRISPR Therapeutics and Genenta Science, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics 2 6 9 0 2.41
Genenta Science 0 0 1 0 3.00

CRISPR Therapeutics presently has a consensus target price of $74.75, suggesting a potential upside of 15.71%. Given CRISPR Therapeutics’ higher probable upside, equities research analysts clearly believe CRISPR Therapeutics is more favorable than Genenta Science.

Insider and Institutional Ownership

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

About CRISPR Therapeutics

(Get Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit

About Genenta Science

(Get Free Report)

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with's FREE daily email newsletter.